JBiSE  Vol.6 No.8 B , August 2013
Proof of concept study to identify candidate biomarkers of fibrosis using high throughput peptide aptamer microarray and validate by enzyme linked immunosorbant assay
Abstract: Background: Nine proteins were identified as putative profibrotic biomarkers in systemic sclerosis (SSc) and an unrelated fibrotic disease in a previously published proteomic study. As the majority of these proteins were orphans of commercially available antibodies, the nine proteins were investigated to determine whether binding peptide aptamers of the Stefin A quadruple mutant-Tracy variant (referred to as “affimers”) could be validated by enzyme linked immunosorbant assay (ELISA) to allow the quantification of these candidate biomarkers in the sera of SSc patients. Materials and Methods: Candidate biomarker peptides were analysed by high throughput affimer microarray to identify binding affimers. Two candidate biomarkers were prioritised, and binding affimers were expressed from genetically modified BL21 competent E. coli strains and purified. These affimers were used in indirect ELISA, and then sandwich ELISA formats against the candidate biomarker recombinant proteins osteonectin and pigment epi-thetlium-derived factor (PEDF). Results: 39 affimers were identified as binders for eight of the nine candidate biomarker peptides were by affimer microarray; six for osteonectin and eleven for PEDF. Two of the six and all eleven were able to recognize physiological concentrations (5 and 1 μg·ml﹣1) of osteonectin and PEDF, respectively by indirect ELISA. In sandwich ELISA format: two affimers were able to detect recombinant PEDF; however, the two affimers identified in indirect ELISA were unable to recognise recombinant osteonectin, and were thus hypothesised to bind to osteonectin at the same binding site. Discussion: SSc is currently an orphan of fully validated biomarkers, which is required for the development of stratified medicine in this field. This approach has laid the groundwork for an affimer based on multiplexed assay, to validate biomarkers in the sera of SSc patients in the future.
Cite this paper: Straw, S. , Ferrigno, P. , Song, Q. , Tomlinson, D. and Galdo, F. (2013) Proof of concept study to identify candidate biomarkers of fibrosis using high throughput peptide aptamer microarray and validate by enzyme linked immunosorbant assay. Journal of Biomedical Science and Engineering, 6, 32-42. doi: 10.4236/jbise.2013.68A2005.

[1]   Moon, K.W., et al. (2011) The correlation between durometer score and modified Rodnan skin score in systemic sclerosis. Rheumatology International, 32, 2465-2470.

[2]   Castro, S.V. and Jimenez, S.A. (2010) Biomarkers in systemic sclerosis. Biomarkers in Medicine, 4, 133-147. doi:10.2217/bmm.09.79

[3]   Del Galdo, F., Shaw, M.A. and Jimenez, S.A. (2010) Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. American Journal of Pathology, 177, 1638-1646. doi:10.2353/ajpath.2010.091095

[4]   Furst, D., et al. (2007) Systemic sclerosis—Continuing progress in developing clinical measures of response. Journal of Rheumatology, 34, 1194-200.

[5]   Matucci-Cerinic, M., et al. (2009) The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology (Oxford), 48, 8-13. doi:10.1093/rheumatology/ken482

[6]   Grobner, T. and Prischl, F.C. (2007) Gadolinium and nephrogenic systemic fibrosis. Kidney International, 72, 260-264. doi:10.1038/

[7]   Abignano, G., et al. (2011) Biomarkers in the management of scleroderma: An update. Current Rheumatology Reports, 13, 4-12. doi:10.1007/s11926-010-0140-z

[8]   Moinzadeh, P., et al. (2012) Biomarkers for skin involvement and fibrotic activity in scleroderma. Journal of the European Academy of Dermatology and Venereology, 26, 267-276. doi:10.1111/j.1468-3083.2011.04206.x

[9]   S, S. (2012) Stratified medicine approach for systemic sclerosis: State of the art and the need for clinical biomarkers. Unpublished Literature Review for Clinical Sciences Programme.

[10]   Clements, P.J., et al. (1993) Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. Journal of Rheumatology, 20, 1892-1896.

[11]   Kaldas, M., et al. (2009) Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis —Assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford), 48, 1143-1146. doi:10.1093/rheumatology/kep202

[12]   Crawford, M., Woodman, R. and Ko Ferrigno, P. (2003) Peptide aptamers: Tools for biology and drug discovery. Briefings in Functional Genomics, 2, 72-79. doi:10.1093/bfgp/2.1.72

[13]   Song, Q., et al. (2011) Peptide aptamer microarrays: Bridging the bio-detector interface. Faraday Discuss, 149, 79-92, 137-157. doi:10.1039/c005376g

[14]   Woodman, R., et al. (2005) Design and validation of a neutral protein scaffold for the presentation of peptide aptamers. Journal of Molecular Biology, 352, 1118-1133. doi:10.1016/j.jmb.2005.08.001

[15]   Stadler, L.K., et al. (2011) Structure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant. Protein Engineering Design & Selection, 24, 751-763. doi:10.1093/protein/gzr019

[16]   Murray, E., et al. (2007) Microarray-formatted clinical biomarker assay development using peptide aptamers to anterior gradient-2. Biochemistry, 46, 13742-13751. doi:10.1021/bi7008739

[17]   Davis, J.J., et al. (2009) Peptide aptamers in label-free protein detection: 2. Chemical optimization and detection of distinct protein isoforms. Analytical Chemistry, 81, 3314-3320. doi:10.1021/ac802513n

[18]   (2012) Aptuscan unique affinity reagents.

[19]   Song, Q., McGonagle, D., et al. (2011) Scannin microbaray identifying protein biomarkers in inflammatory diseases. Leeds Institute of Molecular Medicine.

[20]   Nucleic acid purification.

[21]   Trusheim, M.R., Berndt, E.R. and Douglas, F.L. (2007) Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery, 6, 287-293. doi:10.1038/nrd2251

[22]   Hughes, B. (2009) Developing tools for stratified medicine. Nature Reviews Drug Discovery, 8, 919-920. doi:10.1038/nrd3070

[23]   Ionescu, R., et al. (2010) Repeated teaching courses of the modified Rodnan skin score in systemic sclerosis. Clinical and Experimental Rheumatology, 28, S37-S41.

[24]   Furst, D.E., et al. (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. Journal of Rheumatology, 25, 84-88.

[25]   Postlethwaite, A.E., et al. (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis & Rheumatism, 58, 1810-1822. doi:10.1002/art.23501

[26]   Khanna, D., et al. (2009) Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 60, 1102-1111. doi:10.1002/art.24380

[27]   Rull, G. (2011) Systemic sclerosis (scleroderma).

[28]   Ikuta, Y., et al. (2005) Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clinical Cancer Research, 11, 8079-8088. doi:10.1158/1078-0432.CCR-05-1074

[29]   Yamagishi, S., et al. (2006) Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. Journal of Clinical Endocrinology & Metabolism, 91, 2447-2450. doi:10.1210/jc.2005-2654

[30]   Davis, J.J., et al. (2007) Peptide aptamers in label-free protein detection: 1. Characterization of the immobilized scaffold. Analytical Chemistry, 79, 1089-1096. doi:10.1021/ac061863z

[31]   Laurenson, S., et al. (2011) Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts. Analytical Chemistry, 410, 161-170. doi:10.1016/j.ab.2010.10.038